VRSN
53
3
XEL
67
2
ILMN
32
-3
IPG
49
10
AMAT
36
5
DLTR
34
-4
ETR
68
3
HPE
55
11
AMGN
44
5
K
53
2
CF
59
3
NAVI
41
-3
PBI
60
-5
TGT
25
-24
FRT
39
-2
AKAM
43
3
NOV
58
3
DTE
50
3
COP
56
2
DAL
80
-4
VRSN
53
3
XEL
67
2
ILMN
32
-3
IPG
49
10
AMAT
36
5
DLTR
34
-4
ETR
68
3
HPE
55
11
AMGN
44
5
K
53
2
CF
59
3
NAVI
41
-3
PBI
60
-5
TGT
25
-24
FRT
39
-2
AKAM
43
3
NOV
58
3
DTE
50
3
COP
56
2
DAL
80
-4
Financhill
Back

Perspective Therapeutics 10K Form

Sell
30

CATX
Perspective Therapeutics

Last Price:
3.09
Seasonality Move:
34.33%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CATX News And Ratings

See the #1 stock for the next 7 days that we like better than CATX

CATX Financial Statistics

Sales & Book Value

Annual Sales: $3.55M
Cash Flow: $-26.35M
Price / Cash Flow: 0
Annual Sales: $4.86
Price / Book: 1.43

Profitability

EPS (TTM): -1.46000
Net Income (TTM): $-63.79M
Gross Margin: $817K
Return on Equity: 0%
Return on Assets: 0%

Perspective Therapeutics Earnings Forecast

Key Perspective Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 29 years for CATX is 23.00%.
  • The Selling, General & Administrative Expenses for CATX have been equal to 200.08% of Gross Profit Margin.
  • The Interest Expense is -0.18% of Operating Income.
  • Per Share Earnings over the last 30 years have been positive in 16 years.

Perspective Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CATX
Website: perspectivetherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CATX Technical Analysis vs Fundamental Analysis

Sell
30
Perspective Therapeutics (CATX) is a Sell

Is Perspective Therapeutics a Buy or a Sell?